Key facts
- It has raised $50K; the latest was Accelerator/Incubator in Feb 2025.
- Notable investors include Cambridge Enterprise Ventures, BoxOne Ventures, BlueYard Capital, BioInnovation Institute, Founders at the University of Cambridge — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Xterna
- ·The full record, as it builds
Funding rounds
No funding rounds for Xterna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xterna
Developer of molecular technologies designed to achieve precise targeting using alternative nucleic acids. The company uses enhanced modified nucleic acids to engineer drug delivery resolutions, enabling healthcare professionals with cell-specific targeting.
- Sector
- Healthcare
- HQ
- Hove, United Kingdom
- Founded
- 2023
- Employees
- 5
- Website
- xterna.bio/
- Ownership
- Privately Held (backing)
Xterna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xterna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xterna in its N-PORT filings yet. We sweep new filings monthly.